The final result? “The risk is not zero, but the risk of developing breast cancer from hormonal hormone therapy is very low. Although the WHI trial identified greater health risks than benefits among women in the hormonal therapy user group, the use of estrogens plus progestins was associated with a significant decrease in the incidence of colorectal cancer. No significant excess of cases of breast cancer has been observed five or more years after the cessation of the use of hormonal hormonal therapy or in relation to the duration of use. For women who have had a hysterectomy (surgery to remove the uterus), progestin need not be part of hormone therapy because there is no risk of endometrial cancer.
The cancer risk of HRT varies according to many factors, so treatment must be individualized to identify the most appropriate dose, regimen, duration and route of administration, using the best available evidence, with a periodic reassessment of women's benefit-risk profile. To quantify the risk, if 1000 women in their 50s were taking menopausal hormones for 5 years, it would be expected that an additional ovarian cancer would develop. Several large studies have analyzed possible links between systemic hormone therapy in menopausal women and different types of cancer.
Regardless of the type of hormone replacement therapy you're taking, recent studies show a nearly 40% reduction in cases of colon cancer in postmenopausal people receiving hormone replacement therapy.
To put the risk in numbers, if 10,000 women took EPT for one year, there would be up to 8 more cases of breast cancer per year than if they had not received hormone therapy (HT). Not only is the cancer risk associated with hormone therapy minimal, but it can also help reduce the risk of certain types of cancer in some people.Women who underwent electromagnetic therapy had a lower risk of colorectal cancer, but the cancers they had were more advanced (more likely to have spread to lymph nodes or to distant sites) than those of women who didn't take hormones. EPT is not linked to a higher risk of lung cancer, but it is linked to a higher risk of dying from cancer of lung. There are also studies that suggest that estrogen therapy may improve the survival of people who have already been diagnosed and treated for ovarian cancer. During the intervention phase, the CRI for breast cancer was 1.24 (CI: 1.01—1.5 with the use of CEE-MPA) and 0.79 (CI: 0.62—1.0 with the use of CEE).
Breast cancer is the most commonly diagnosed cancer and is the leading cause of cancer death in women. Hormonal therapy for menopause and the risk of ovarian cancer in European prospective research on cancer and nutrition.
